Moderator Douglas Pahl, MD, interviews authors Alex Mierke, MD, and Omar Ramos, MD, about their article titled, "Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain." Drs. Mierke and Ramos discuss what is already known about stem cell therapies and what still may lie ahead in this ever-changing medical landscape.

Access the article here.

Disclosures:

Mierke, Alex : Nothing to Disclose  

Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (less than 1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Astrazeneca (A, Outside 12-Month Requirement), Boston Scientific (B, Outside 12-Month Requirement), DePuy/Synthes (A, Outside 12-Month Requirement), DJO (A, Outside 12-Month Requirement), Globus (A, Outside 12-Month Requirement), Horizon (A, Outside 12-Month Requirement), Medtronic (A, Outside 12-Month Requirement), Stryker (B, Outside 12-Month Requirement), Zimmer/Biomet (C, Outside 12-Month Requirement).

Ramos, Omar: Nothing to Disclose

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+